Who is on it, and how far along Every drug ChEMBL records acting on CD40, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Phase 211 CDX-1140 CDX-1140 SponsorCelldex Therapeutics ModalityOther ActionAgonist Open trials7 CD40 ligand CD40 ligand SponsorMemgen ModalityOther ActionAgonist Open trials4 PG-102 PG-102 SponsorRani Therapeutics ModalityOther ActionInhibitor Open trials4 Selicrelumab Selicrelumab SponsorRoche ModalityAntibody ActionAgonist Open trials1 Sotigalimab Sotigalimab SponsorApexigen America, Inc. ModalityAntibody ActionAgonist Open trials1 Bleselumab Bleselumab SponsorAstellas Pharma ModalityAntibody ActionInhibitor Open trials0 Dacetuzumab Dacetuzumab SponsorPfizer ModalityAntibody ActionInhibitor Open trials0 Giloralimab Giloralimab SponsorAbbVie ModalityAntibody ActionAgonist Open trials0 Iscalimab Iscalimab SponsorNovartis Pharmaceuticals ModalityAntibody ActionInhibitor Open trials0 Lucatumumab Lucatumumab SponsorNovartis Pharmaceuticals ModalityAntibody ActionAntagonist Open trials0 Teneliximab Teneliximab SponsorNot known ModalityAntibody ActionPartial agonist Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. Drug Furthest stage Sponsor Modality Action Open trials CDX-1140 Phase 2 Celldex Therapeutics OtherAgonist Tumor necrosis factor receptor superfamily member 5 agonist 7 CD40 ligand Phase 2 Memgen OtherAgonist Tumor necrosis factor receptor superfamily member 5 agonist 4 PG-102 Phase 2 Rani Therapeutics OtherInhibitor Tumor necrosis factor receptor superfamily member 5 inhibitor 4 Selicrelumab Phase 2 Roche AntibodyAgonist Tumor necrosis factor receptor superfamily member 5 agonist 1 Sotigalimab Phase 2 Apexigen America, Inc. AntibodyAgonist Tumor necrosis factor receptor superfamily member 5 agonist 1 Bleselumab Phase 2 Astellas Pharma AntibodyInhibitor Tumor necrosis factor receptor superfamily member 5 inhibitor 0 Dacetuzumab Phase 2 Pfizer AntibodyInhibitor Tumor necrosis factor receptor superfamily member 5 inhibitor 0 Giloralimab Phase 2 AbbVie AntibodyAgonist Tumor necrosis factor receptor superfamily member 5 agonist 0 Iscalimab Phase 2 Novartis Pharmaceuticals AntibodyInhibitor Tumor necrosis factor receptor superfamily member 5 inhibitor 0 Lucatumumab Phase 2 Novartis Pharmaceuticals AntibodyAntagonist Tumor necrosis factor receptor superfamily member 5 antagonist 0 Teneliximab Phase 2 — AntibodyPartial agonist Tumor necrosis factor receptor superfamily member 5 partial agonist 0
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 15 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus PG-102 Phase 2 Not yet recruiting ProGen. Co., Ltd. Jul 1, 2026 Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus PG-102 Phase 2 Not yet recruiting ProGen. Co., Ltd. Sep 23, 2025 Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer CDX-1140 Phase 2 Recruiting National Cancer Institute (NCI) May 20, 2025 An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers. PG-102 Phase 1 Recruiting RANI Therapeutics Mar 24, 2025 Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes PG-102 Phase 2 Active, not recruiting ProGen. Co., Ltd. Dec 2, 2024 Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D) CD40 ligand Phase 1 / Phase 2 Active, not recruiting University of Chicago Mar 12, 2024 A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) CDX-1140 Phase 1 / Phase 2 Recruiting National Cancer Institute (NCI) May 9, 2023 Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) CDX-1140 Phase 1 Active, not recruiting Providence Health & Services Apr 27, 2022 Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer CDX-1140 Phase 2 Recruiting Roswell Park Cancer Institute Feb 9, 2022 MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors CD40 ligand Phase 1 Recruiting Memgen, Inc. Oct 13, 2021 CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer CD40 ligand, CDX-1140 Phase 1 Recruiting University of Texas Southwestern Medical Center Sep 1, 2021 In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors CD40 ligand, CDX-1140 Phase 1 Active, not recruiting University of Southern California Nov 4, 2020 Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) CDX-1140 Phase 1 Active, not recruiting Providence Health & Services Aug 20, 2020 A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer Selicrelumab Phase 1 / Phase 2 Recruiting Hoffmann-La Roche Feb 6, 2018 Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer Sotigalimab Phase 1 Active, not recruiting M.D. Anderson Cancer Center Nov 9, 2015
Diseases most associated with it Open Targets association score, 0 to 1; all associations Hyper-IgM syndrome type 3 0.79 Hyper-IgM syndrome type 3 Value0.79 Rheumatoid arthritis 0.61 Rheumatoid arthritis Value0.61 Open Graves disease 0.58 Graves disease Value0.58 Open Inflammatory bowel disease 0.50 Inflammatory bowel disease Value0.50 Open Crohn disease 0.50 Crohn disease Value0.50 Bipolar disorder 0.47 Bipolar disorder Value0.47 Open Thyrotoxicosis 0.46 Thyrotoxicosis Value0.46 Non-Hodgkin lymphoma 0.46 Non-Hodgkin lymphoma Value0.46 Open Kawasaki disease 0.45 Kawasaki disease Value0.45 Mathematical ability 0.45 Mathematical ability Value0.45 ACPA-positive rheumatoid arthritis 0.45 ACPA-positive rheumatoid arthritis Value0.45 Post-traumatic stress disorder 0.41 Post-traumatic stress disorder Value0.41 Open Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1250358 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. Gene name, function (UniProt P25942 , CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets